Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03761914
Title Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sellas Life Sciences Group
Indications

colorectal cancer

ovarian cancer

fallopian tube cancer

Advanced Solid Tumor

peritoneum cancer

acute myeloid leukemia

lung small cell carcinoma

triple-receptor negative breast cancer

Therapies

Galinpepimut-S

Galinpepimut-S + Pembrolizumab

Pembrolizumab

Sargramostim

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
St. Joseph Heritage Healthcare Santa Rosa California 95403 United States Details
Innovative Clinical Research Institute (ICRI) Whittier California 90603 United States Details
Miami Cancer Institute at Baptist Health, Inc. Miami Florida 33176 United States Details
Memorial Sloan Kettering Cancer Center Basking Ridge New Jersey 07920 United States Details
Memorial Sloan Kettering Cancer Center Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Cancer Center Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Cancer Center Commack New York 11725 United States Details
Memorial Sloan Kettering Cancer Center Harrison New York 10604 United States Details
Memorial Sloan Kettering Cancer Center Nassau New York 11553 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Oncology Hematology Care, Inc. Cincinnati Ohio 45242 United States Details
MD Anderson Cancer Center Houston Texas 77054 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field